NewEdge Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

NewEdge Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-900	Closed	-$981	–	3480
2023 Q1	$981	Hold	900	–	–	﹤0.01%	3158
2022 Q4	$1	Buy	+900	New	+$1.46K	﹤0.01%	3978

Other funds holding ADAP

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NewEdge Advisors's ADAP Position: Q2 2023 in Review

NewEdge Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2023, closing a stake of 900 shares — an estimated $981 sold.

NewEdge Advisors first reported a position in ADAP in Q4 2022 and held it in 2 quarters. The position peaked at $981 in Q1 2023. 89 funds tracked by Wall St. Rank hold ADAP as of Q2 2023.

NewEdge Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2023 after selling out during the quarter.
NewEdge Advisors sold 900 Adaptimmune Therapeutics shares in Q2 2023, an estimated $981.
NewEdge Advisors first reported a position in Adaptimmune Therapeutics in Q4 2022 and held it in 2 quarters.
NewEdge Advisors's Adaptimmune Therapeutics position peaked at $981 in Q1 2023.
89 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2023.

Based on NewEdge Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.